



**This document is effective 5/5/2021 and is subject to revisions based on the rapidly changing environment.**

---

## **Kaiser Permanente Insurance Company (KPIC) Claims Administration**

**The content of this FAQ pertains to members of KPIC. For members covered by Kaiser Foundation Health Plan, please see the separate COVID-19 FAQ.**

### **COVID-19: Claims Processing FAQ for Providers | V17, Updated as of 05/05/2021**

---

- 1. Will Kaiser Permanente Insurance Company continue to accept, and process claims submitted during the COVID-19 pandemic?**

Yes. Kaiser Permanente Insurance Company will continue to accept, and process claims according to industry standard, state and federal guidelines.
- 2. Do you expect COVID-19 to impact Kaiser Permanente Insurance Company Claims Administration business operations? Is there risk of claims payments being delayed?**

No, we do not anticipate any delays. We have robust business continuity plans in place internally and at our claims third party administrators to ensure we meet claims timeliness requirements. Should anything change unexpectedly, we will keep providers and regulators informed about any anticipated delays.
- 3. Will timely filing requirements for claims be waived, if providers' claims submissions are delayed due to impacts from COVID-19?**

Kaiser Permanente Insurance Company will continue to apply all timely filing requirements, except when regulators have issued orders explicitly suspending or modifying the requirements. This policy may be revised or updated, as appropriate, based on the rapidly changing environment
- 4. Will claims be held if they have a COVID-19 diagnosis?**

No, they will not be held. They will be processed according to our standard processing guidelines.
- 5. Will Kaiser Permanente Insurance Company waive the requirement for precertification for some or all claims in light of COVID-19?**

At this time, Kaiser Permanente Insurance Company is only waiving precertification for claims related to testing and screening of COVID-19. We will continue to apply all other authorization requirements, except when regulators have issued orders explicitly mandating suspension or modification of medical management requirements. This policy may be revised or updated, as appropriate, based on the rapidly changing environment.
- 6. Should providers collect cost sharing for COVID-19 screening, diagnosis, testing, or treatment services from our members?**

**Please note:** Some plans may require member cost share. For members in the following plans please contact the customer service phone number on the back of the Member's Id Card to confirm



benefits and member cost share: All Self-Funded Plans, CVS EPO, and Kaiser Permanente School of Medicine.

For all other KPIC plans, the zero-dollar cost sharing for screening and testing is effective for dates of service between March 5<sup>th</sup>, 2020 through December 31, 2021.

The zero-dollar also applies for contracted/in network treatment services for all dates of service (admissions) from April 1, 2020 through the end of the federal public health emergency and the zero dollar cost sharing for treatment services will apply for all dates of service (admissions) from April 1, 2020 through July 31, 2021, unless superseded by government action or extended by Kaiser Permanente Insurance Company, respectively. Former HHS Secretary Azar declared the public health emergency pursuant to section 319 of the Public Health Service Act as of Jan. 26, 2020 and has been extended every 90 days until the declaration expires or is ended. The current extension expires on July 21, 2021.

Non-contracted/ out of network treatment services may require member cost share. Please contact the customer service phone number on the back of the Member's ID Card to confirm benefits and cost share.

**7. What are the requirements for submitting COVID-19 related claims?**

Please use the scenarios below to find the most specific and accurate diagnosis code. Using these codes will support claims processing associated with COVID-19 screening, diagnosis, testing and treatment services.

**Phase 2: COVID-19 Code Set Implementation no later than 05/07/2021**

Legend:	
Red	Remove from code set
Green	Addition to code set
White	No Change

**COVID-19 SCREENING**

**COVID-19 Screening Office Visits:  
One code from each table (Table 1 - 3)**

**Diagnosis Code:  
Any Dx below on any position of the claim with any Place of Service (Except 41 & 42)**

<b>Table 1</b>	
Any Position on the Claim	
<b>B34.2</b>	Coronavirus Infection, Unspecified
<b>B34.9</b>	Viral infection, unspecified
<b>B97.29</b>	Other coronavirus as the cause of diseases classified elsewhere
<b>J12.89</b>	Other viral pneumonia
<b>J20.8</b>	Acute bronchitis due to other specified organisms
<b>J22</b>	Unspecified acute lower respiratory infection
<b>J80</b>	Acute respiratory distress syndrome
<b>Z03.818</b>	Encounter for observation for suspected exposure to other biological agents ruled out
<b>Z11.52</b>	Encounter for screening for COVID-19 <b>(Effective 1/1/21)</b>
<b>Z11.59</b>	Encounter for screening for other viral diseases
<b>Z20.822</b>	Contact with and (suspected) exposure to COVID-19 <b>(Effective 1/1/21)</b>
<b>Z20.828</b>	Contact with and (suspected) exposure to other viral communicable diseases
<b>COVID-19 IMMUNIZATION</b>	
<b>Table 1a</b>	
<b>Z23</b>	Encounter for Immunization

<b>Evaluation &amp; Management Code Ranges</b>		
<b>Table 2</b>		
<b>Code Range</b>		<b>Evaluation &amp; Management</b>
<b>Start</b>	<b>End</b>	<b>Type</b>
99051	99051	Service(s) provided in the office during regularly scheduled evening, weekend, or holiday office hours, in addition to basic service
99201	99215	Office
99217	99220	Observation
99221	99223	Initial Hospital Care
99224	99226	Subsequent Observation Care
99231	99233	Subsequent Hospital Care
99234	99236	Inpatient Hospital
99238	99239	Hospital Discharge
99241	99245	Office Consult
99251	99255	Inpatient Consult

99281	99288	Emergency Department
99291	99292	Critical Care
99304	99310	Initial Nursing Facility
99315	99316	Nursing Facility Discharge
99324	99337	Rest Home
99339	99340	Domiciliary or rest home
99341	99350	Home Visit
99354	99357	Prolonged E/M Services
99358	99359	Prolonged E/M Services
99421	99423	Online
99441	99443	Telephone
99446	99449	Interprofessional telephone/Internet/electronic health record assessment and management service
99451	99452	Interprofessional telephone/Internet/electronic health record assessment and management service
99468	99476	Neonatal & Pediatric Critical Care
99477	99480	Intensive Care
99495	99496	Transitional Care Management
99499	99499	Unlisted E/M Service

<b>Medical Specialty</b>	
<b>Table 3</b>	
Adult Care	Adult Care
Allergy, Asthma & Immunology	Allergy, Asthma and Immunology
Allergy, Asthma & Immunology	Pediatrics, Allergy, Asthma and Immunology
Allergy, Asthma & Immunology	ALLERGY
Allergy, Asthma & Immunology	OTOLARYNGIC ALLERGY
Critical Care Medicine	Critical Care Medicine
Critical Care Medicine	NURSE PRACTITIONER, CRITICAL CARE MED
Critical Care Medicine	REGISTERED NURSE, CRITICAL CARE MEDICINE
Emergency Medicine	Emergency Medicine

Ear, nose & throat	Otolaryngology
Family Care	Family Care
Family Practice	Family Practice
Family Practice	Family Practice Res
Family Practice	Family Practice N.P.
Family Practice	Family Practice P.A.
General Practice	General Practice
General Practitioner	General Practitioner
Geriatric Medicine	Geriatric Medicine
Geriatric Medicine	Geriatric Medicine SP
Hospital Medicine	Hospital Medicine
Infectious Disease	Infectious Diseases
Internal Medicine	Internal Medicine
Internal Medicine	INTERNAL MED - ALLERGY & IMMUNOLOGY
Internal Medicine	INTERNAL MEDICINE, ADOLESCENT MEDICINE
Internal Medicine	INTERNAL MEDICINE, GERIATRIC MEDICINE
Laboratory	Laboratory
Laboratory	CLINICAL PATHOLOGY/LABORATORY MEDICINE
Laboratory	CLINICAL MEDICAL LABORATORY
Laboratory	MEDICAL LABORATORY
Medical P.A.	Medical P.A.
Nephrology	Nephrology
Nurse	Nursing, General
Nurse Practitioner	Nurse Practitioner
Obstetrics & Gynecology	Obstetrics & Gynecology, Maternal Fetal
Obstetrics & Gynecology	Obstetrics
Obstetrics & Gynecology	Obstetrics & Gynecology
Obstetrics & Gynecology	Gynecology

Obstetrics & Gynecology	GYNECOLOGY, OBG
Obstetrics & Gynecology	Obstetrical Res
Obstetrics & Gynecology	Gynecology Res
Obstetrics & Gynecology	Ob/Gyn N.P.
Obstetrics & Gynecology	NURSE PRACTITIONER, OB/GYN
Obstetrics & Gynecology	OBSTETRICS & GYNECOLOGY, CRITICAL CARE MEDICINE
Obstetrics & Gynecology	OBESITY MEDICINE, OBSTETRICS & GYNECOLOGY
Pathology	Pathology
Pathology	Pathology, Anatomic
Pathology	Pathology, Clinical
Pathology	Pathology, Chemical
Pathology	PATHOLOGY: CHEMICAL PATHOLOGY
Pediatrics	Pediatrics, Critical Care
Pediatrics	Pediatrics, Neonatology
Pediatrics	Pediatrics
Pediatrics	Pediatric Emergency Medicine
Pediatrics	Pediatric Intensive Care
Pediatrics	Pediatrics, Radiology
Pediatrics	Pediatric Res
Pediatrics	Pediatric N.P.
Pediatrics	Pediatric P.A.
Pediatrics	Pediatric Care
Pediatrics	PEDIATRICS-HOSPITAL MEDICINE
Pediatrics	PEDIATRIC PATHOLOGY
Pediatrics	NURSE PRACTITIONER, PEDIATRICS
Pediatrics	SKILLED NURSING FACILITY NURSING CARE, PEDIATRIC
Pediatrics	CLIN NURSE SPECIALIST, PEDIATRICS

Pediatrics	EMERGENCY MEDICINE, PEDIATRIC
Pediatrics	PEDIATRICS, CLINICAL & LABORATORY IMMUNOLOGY
Pediatrics	REGISTERED NURSE, PEDIATRICS
Pediatrics	PEDIATRICS, ADOLESCENT MEDICINE
Pediatrics	NURSE PRACTITIONER, PEDIATRICS CRITICAL CARE
Pediatrics	MEDICAL TOXICOLOGY, PEDIATRICS
Pediatrics	REGISTERED RESPIRATORY THERAPIST, NEONATAL/PEDIATRICS
Pediatrics, Infectious Disease	Pediatrics, Infectious Disease
Pediatrics, Pulmonology	Pediatrics, Pulmonology
Pharmacist	Pharmacist Practitioner
Physician Assistant	Physician Assistant
Physician Assistant	Physician Assistant - Medical
Primary Care	Ambulatory Healthcare Facility Primary Care
Pulmonary Disease	Pulmonary Disease
Pulmonary Disease	Pulmonary Medicine
Pulmonary Disease	CERTIFIED RESPIRATORY THERAPIST, PULMONARY DIAGNOSTICS
Pulmonary Disease	CERTIFIED RESPIRATORY THERAPIST, PULMONARY FUNCTION TECH
Pulmonary Disease	CERTIFIED RESPIRATORY THERAPIST, PULMONARY REHABILITATION
Pulmonary Disease	PULMONARY FUNCTION TECHNOLOGIST
Pulmonary Disease	REGISTERED RESPIRATORY THERAPIST, PULMONARY DIAGNOSTICS
Pulmonary Disease	REGISTERED RESPIRATORY THERAPIST, PULMONARY FUNCTION TECH
Pulmonary Disease	REGISTERED RESPIRATORY THERAPIST, PULMONARY REHABILITATION
Radiology	Radiology
Radiology	Radiology, Diagnostic

Radiology	Radiology Res
Radiology	RADIOLOGY DIAGNOSTIC ULTRASOUND
Registered Nurse	Registered Nurse
Urgent care	Urgent Care
Urgent care	Urgent Care II
Urgent care	Urgent Care II
Urgent care	z Urgent Care Facility
Urgent care	AMBULATORY HEALTH CARE FACILITIES, URGENT CARE

**COVID-19 S Ancillary Testing Services:  
Diagnosis Code from Table 1 Required**

Table 4	
71045	Radiologic examination, chest; single view
71046	Radiologic examination, chest; 2 views
71047	Radiologic examination, chest; 3 views
71048	Radiologic examination, chest; 4 or more views
71250	Computed tomography, thorax; without contrast material
71260	Computed tomography, thorax; with contrast material(s)
71270	Computed tomography, thorax; without contrast material, followed by contrast material(s) and further sections
99000	Handling and/or conveyance of specimen for transfer from the office to a laboratory
99001	Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)

**COVID-19: Laboratory Testing  
Diagnosis Code Not Required**

Table 5	
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected <b>(Effective 5/20/2020)</b>
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome



	coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected <b>(Effective 6/25/2020)</b>
<b>0224U</b>	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed <b>(Effective 6/25/2020)</b>
<b>0225U</b>	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected <b>(Effective 8/10/20)</b>
<b>0226U</b>	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(Coronavirus disease [COVID-19]), ELISA, plasma, serum <b>(Effective 8/10/20)</b>
<b>0240U</b>	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected <b>(Effective 10/6/20)</b>
<b>0241U</b>	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected <b>(Effective 10/6/20)</b>
<b>86328</b>	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) <b>(Effective 4/10/2020)</b>
<b>86408</b>	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(Coronavirus disease [COVID-19]); screen <b>(Effective 8/10/20)</b>
<b>86409</b>	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(Coronavirus disease [COVID-19]); titer <b>(Effective 8/10/20)</b>
<b>86413</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative <b>(Effective 9/10/20)</b>
<b>86769</b>	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) multiple-step method <b>(Effective 4/10/2020)</b>
<b>87426</b>	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; adenovirus enteric types 40/41; severe

	acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) <b>(Effective 6/25/2020)</b>
<b>87428</b>	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; adenovirus enteric types 40/41; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B <b>(Effective 11/10/20)</b>
<b>87635</b>	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique <b>(Effective 3/13/2020)</b>
<b>87636</b>	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique <b>(Effective 10/6/20)</b>
<b>87637</b>	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique <b>(Effective 10/6/20)</b>
<b>87798</b>	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism
<b>87811</b>	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) <b>(Effective 10/6/20)</b>
<b>C9803</b>	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <b>(Effective 3/1/2020)</b>
<b>D0604</b>	Antigen testing for a public health related pathogen, including coronavirus <b>(Effective 1/1/21) - Pay claim if no dental coverage</b>
<b>D0605</b>	Antibody testing for a public health related pathogen, including coronavirus <b>(Effective 1/1/21) - Pay claim if no dental coverage</b>
<b>D0606</b>	Molecular testing for a public health related pathogen, including coronavirus (Effective 3/15/2021) - Pay claim if no dental coverage
<b>G2023</b>	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source. <b>(Effective 3/1/2020)</b>

<b>G2024</b>	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a SNF or by a laboratory on behalf of a HHA, any specimen source. <b>(Effective 3/1/2020)</b>
<b>U0001</b>	Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel SARS-CoV-2 <b>(Effective 4/1/2020)</b> <b>*for dates of service on or after 2/4/2020</b>
<b>U0002</b>	Novel Coronavirus Test Panel SARS-CoV-2/2019-nCoV <b>(Effective 4/1/2020)</b> <b>*for dates of service on or after 2/4/2020</b>
<b>U0003</b>	Infectious agent detection by nucleic acid (DNA or RNA); Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R <b>(Effective 4/14/2020)</b> <b>*for dates of service on or after 3/18/2020</b>
<b>U0004</b>	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R <b>(Effective 4/14/2020)</b> <b>*for dates of service on or after 3/18/2020</b>
<b>U0005</b>	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date and time of specimen collection. <i>(List separately in addition to either HCPCS code U0003 or U0004)</i> <b>(Effective 1/1/2021)</b>
<b>COVID-19: Other Diagnosis Code Not Required</b>	
<b>99072</b>	Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency as defined by law, due to respiratory-transmitted infectious disease <b>(Effective 9/10/20)</b>

**COVID-19 Modifier: (At the line Level)  
No Other Code Requirements**

<b>CS</b>	Cost sharing for COVID-19 testing and visits related to testing <b>*for dates of service on or after 3/18/2020</b>
-----------	---

**Ancillary Laboratory Services**

<b>36415</b>	Collection of venous blood by venipuncture (Only when billed with antibody tests 0224U, 86328, 86408, 86409, 86413, 86769, 87426, 87428, 87811, D0604, D0605)
--------------	---

## COVID-19 TREATMENT

Diagnosis for confirmed COVID-19 infection	
<b>U07.1</b>	COVID-19 Acute Respiratory Distress ( <b>Effective 4/1/2020</b> )

### COVID-19: Laboratory Testing Diagnosis from Table 1 Required for Hospital Outpatient

Table 6	
<b>0202U</b>	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected ( <b>Effective 5/20/2020</b> )
<b>0223U</b>	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected ( <b>Effective 6/25/2020</b> )
<b>0224U</b>	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed ( <b>Effective 6/25/2020</b> )
<b>0225U</b>	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected ( <b>Effective 8/10/20</b> )
<b>0226U</b>	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(Coronavirus disease [COVID-19]), ELISA, plasma, serum ( <b>Effective 8/10/20</b> )
<b>0240U</b>	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected ( <b>Effective 10/6/20</b> )

0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected <b>(Effective 10/6/20)</b>
86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) <b>(Effective 4/10/2020)</b>
86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(Coronavirus disease [COVID-19]); screen <b>(Effective 8/10/20)</b>
86409	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(Coronavirus disease [COVID-19]); titer <b>(Effective 8/10/20)</b>
86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative <b>(Effective 9/10/20)</b>
86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) multiple-step method <b>(Effective 4/10/2020)</b>
87426	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; adenovirus enteric types 40/41; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) <b>(Effective 6/25/2020)</b>
87428	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; adenovirus enteric types 40/41; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B <b>(Effective 11/10/20)</b>
87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique <b>(Effective 3/13/2020)</b>
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique <b>(Effective 10/6/20)</b>

<b>87637</b>	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique <b>(Effective 10/6/20)</b>
<b>87798</b>	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism
<b>87811</b>	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) <b>(Effective 10/6/20)</b>
<b>C9803</b>	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <b>(Effective 3/1/2020)</b>
<b>D0604</b>	Antigen testing for a public health related pathogen, including coronavirus <b>(Effective 1/1/21) - Pay claim if no dental coverage</b>
<b>D0605</b>	Antibody testing for a public health related pathogen, including coronavirus <b>(Effective 1/1/21) - Pay claim if no dental coverage</b>
<b>D0606</b>	Molecular testing for a public health related pathogen, including coronavirus <b>(Effective 3/15/2021) - Pay claim if no dental coverage</b>
<b>G2023</b>	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source. <b>(Effective 3/1/2020)</b>
<b>G2024</b>	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a SNF or by a laboratory on behalf of a HHA, any specimen source. <b>(Effective 3/1/2020)</b>
<b>U0001</b>	Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel SARS-CoV-2 <b>(Effective 4/1/2020)</b> <b>*for dates of service on or after 2/4/2020</b>
<b>U0002</b>	Novel Coronavirus Test Panel SARS-CoV-2/2019-nCoV <b>(Effective 4/1/2020)</b> <b>*for dates of service on or after 2/4/2020</b>
<b>U0003</b>	Infectious agent detection by nucleic acid (DNA or RNA); Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R <b>(Effective 4/14/2020)</b> <b>*for dates of service on or after 3/18/2020</b>
<b>U0004</b>	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R <b>(Effective 4/14/2020)</b> <b>*for dates of service on or after 3/18/2020</b>



<b>U0005</b>	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date and time of specimen collection. <b><u>(List separately in addition to either HCPCS code U0003 or U0004) Effective 1/1/2021)</u></b>
--------------	--

**COVID-19: Other**

<b>99072</b>	Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency as defined by law, due to respiratory-transmitted infectious disease <b>(Effective 9/10/20)</b>
--------------	--

**Ancillary Laboratory Services**

<b>36415</b>	Collection of venous blood by venipuncture (Only when billed with antibody tests 0224U, 86328, 86408, 86409, 86413, 86769, 87426, 87428, 87811, D0604, D0605)
--------------	---

**36415**

**Monoclonal Antibody Therapy Administration**

**Table 7a**

<b>M0243</b>	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring
<b>M0239</b>	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring <b>(Obsolete effective DOS 4/16/21)</b>
<b>M0245</b>	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring

**Monoclonal Antibody Therapy Drug Supply**

**Table 7b**

<b>Q0243</b>	Injection, casirivimab and imdevimab, 2400 mg <b>(Provided at no cost and should not billed on a claim)</b>
<b>Q0239</b>	Injection, bamlanivimab-xxxx, 700 mg <b>(Provided at no cost and should not billed on a claim) (Obsolete effective DOS 4/16/21)</b>
<b>Q0245</b>	Injection, bamlanivimab and etesevimab, 2100 mg (Provided at no cost and should not billed on a claim)

**COVID-19 Modifier: (At the Line Level)  
No Other Code Requirements**

<b>CS</b>	Cost sharing for COVID-19 testing and visits related to testing <b>*for dates of service on or after 3/18/2020</b>
-----------	---

Modifiers (Optional) *Medicare required	
CR	Catastrophe/Disaster

Facility Condition Code (Optional) *Medicare required	
DR	Disaster related

## COVID-19 VACCINATIONS

### Vaccine Administration No additional qualifiers needed

Table 8	
<b>0001A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose <b>(Pfizer)</b>
<b>0002A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose <b>(Pfizer)</b>
<b>0011A</b>	Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose <b>(Moderna)</b>
<b>0012A</b>	Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose <b>(Moderna)</b>
<b>0021A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage; first dose <b>(AstraZeneca)</b>
<b>0022A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage; second dose <b>(AstraZeneca)</b>



<b>0031A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage, single dose ( <b>Janssen</b> )
<b>D1701</b>	SARSCOV2 COVID-19 VAC Administration mRNA 30mcg/0.3mL IM DOSE 1 ( <b>Pfizer</b> ) Effective 3/15/2021
<b>D1702</b>	SARSCOV2 COVID-19 VAC Administration mRNA 30mcg/0.3mL IM DOSE 2 ( <b>Pfizer</b> ) Effective 3/15/2021
<b>D1703</b>	SARSCOV2 COVID-19 VAC Administration mRNA 100mcg/0.5mL IM DOSE 1 ( <b>Moderna</b> ) Effective 3/15/2021
<b>D1704</b>	SARSCOV2 COVID-19 VAC Administration mRNA 100mcg/0.5mL IM DOSE 2 ( <b>Moderna</b> ) Effective 3/15/2021
<b>D1705</b>	SARSCOV2 COVID-19 VAC Administration rS-ChAdOx1 5x10 <sup>10</sup> VP/.5mL IM DOSE 1 ( <b>AstraZeneca</b> ) Effective 3/15/2021
<b>D1706</b>	SARSCOV2 COVID-19 VAC Administration rS-ChAdOx1 5x10 <sup>10</sup> VP/.5mL IM DOSE 2 ( <b>AstraZeneca</b> ) Effective 3/15/2021
<b>D1707</b>	SARSCOV2 COVID-19 VAC Administration Ad26 5x10 <sup>10</sup> VP/.5mL IM SINGLE DOSE ( <b>Janssen</b> ) Effective 3/15/2021

### COVID-19 Vaccine

No additional qualifiers needed

**When COVID-19 doses for vaccine are provided by the government without charge, only bill for the administration. Don't include the drug codes on the claim.**

Table 9

<b>91300</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use ( <b>Pfizer</b> )
<b>91301</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use ( <b>Moderna</b> )
<b>91302</b>	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1

	(ChAdOx1) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage, for intramuscular use ( <b>AstraZeneca</b> )
<b>91303</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> . viral particles/0.5mL dosage, for intramuscular use ( <b>Janssen</b> )

**Diagnosis Position & Cost Share Requirements for Testing & Treatment**

	Place of Service / LOB	Claim Type	POS (Tapestry AP maps to Bill Type)	Qualifiers	Dx Position	Adjudication Level	Cost Share
<b>Testing</b>	Professional (adjudicate with Dx at header level)	CMS	Any (except 41, 42, 51, 52, 55, 56, 57, 58, 65)	COVID Diagnosis Table 1 + E&M Table 2 + Provider Specialty Table 3	Any	Claim	\$0 entire claim
	Lab	CMS	Any (except 41 & 42)	Lab CPT Table 5	Not applicable	Line	\$0 lab only
	Radiology & Ancillary	CMS	Any (except 41, 42, 51, 52, 55, 56, 57, 58, 65)	Diagnosis Table 1 + Radiology & Ancillary Table 4	Primary (adjudicate with Dx at the header level)	Line	\$0 radiology and ancillary only
	Hospital ED & Urgent Care	CMS & UB	20, 23	COVID Lab CPT Table 5 + COVID Diagnosis Table 1	Any	Claim	\$0 entire claim
	Hospital outpatient	CMS & UB	12, 19, 22	Lab CPT Table 5	Not applicable	Line	\$0 lab only
	Hospital ambulatory surgery center	CMS & UB	24	Lab CPT Table 5	Not applicable	Line	\$0 lab only
	All services	CMS & UB	Any (except 41 & 42)	CS Modifier	Not applicable	Line	\$0 line level
	All services	CMS & UB	Any (except 41 & 42)	CPT 36415 (Only when billed with antibody tests 0224U, 86328, 86408, 86409, 86413, 86769, 87426, 87428, 87811, D0604, D0605)	Not applicable	Line	\$0 line level
<b>Treatment IP</b>	Inpatient & Hospice	CMS & UB	21, 31, 32, 33, 34, 61 (Except 41 & 42)	Diagnosis U07.1	Any	Claim	\$0 entire claim

<b>Treatment OP</b>	Hospital ED & Urgent Care	CMS & UB	20, 23	Diagnosis U07.1	Any	Claim	\$0 entire claim
	Hospital outpatient	CMS & UB	12,19, 22	Diagnosis U07.1	Any	Claim	\$0 entire claim
	ESRD clinic	CMS & UB	65	Diagnosis U07.1	Primary	Claim	\$0 entire claim
	Outpatient treatment	CMS	Any (except 41, 42, 51, 52, 55, 56, 57, 58, 65)	Diagnosis U07.1	Any	Claim	\$0 entire claim
<b>Vaccine Administration</b>	Commercial, Fully Insured, KPIC, Self Funding	CMS & UB	Any	HCPCS Code from Table 8	Any	Line	\$0 line level
	KP Medicare & KP Medicaid	CMS & UB	Any	HCPCS Code from Table 8	Any	Line	Deny claim Lines in Tapestry
<b>Monoclonal Antibody Therapy Administration</b>	KP Medicare	CMS & UB	Any	HCPCS Code from Table 7a	Any	Line	Deny claim Lines in Tapestry
<b>Monoclonal Antibody Therapy Administration</b>	MediCal (California Only)	CMS & UB	Any	HCPCS Code from Table 7a	Any	Line	\$0 line level
<b>Vaccine Supply (DRUG)</b>	All LOB	CMS & UB	Any	HCPCS Code from Table 9	Any	Line	Deny claim Lines in Tapestry
<b>Monoclonal Antibody Therapy Supply (DRUG)</b>	All LOB	CMS & UB	Any	HCPCS Code from Table 7b	Any	Line	Deny claim Lines in Tapestry

**Place of Service (POS) List:**

[https://www.cms.gov/Medicare/Coding/place-of-service-codes/Place\\_of\\_Service\\_Code\\_Set](https://www.cms.gov/Medicare/Coding/place-of-service-codes/Place_of_Service_Code_Set)

**8. What are the requirements for submitting COVID-19 related claims? [ALTERNATE RESPONSE]**

Please use the appropriate COVID-19 codes that have been established to indicate COVID-19 screening, diagnosis, testing and treatment on your claims. For more information related to CDC's ICD-10-CM Official Coding and Reporting Guidelines October 1, 2020 – September 30, 2021, <https://www.cdc.gov/nchs/data/icd/10cmguidelines-FY2021.pdf> . If you do not charge a cost share because you are providing a service related to



COVID-19, please utilize the CS modifier on your claim to indicate this when appropriate.

**9. What diagnosis do the providers/groups use for Non COVID-19 related issues?**

Providers should continue to follow standard ICD-10 coding guidelines for any non COVID-19-related issues.

**10. Can providers submit claims for precertification office visits that were converted to telehealth visits?**

We appreciate your efforts to limit the spread of COVID-19 in the community. You may convert precertification office visits to telehealth visits, where clinically appropriate and technology is available, without seeking additional precertification from Kaiser Permanente Insurance Company.

Please ensure that you request a visual verification of members' Kaiser Permanente Insurance Company Identification Card during telehealth visits, just as you would in-person in your medical office setting.

All members are covered for telehealth visits and while most members receive no-charge for telehealth visits, please contact the customer service phone number on the back of the Member's ID Card to confirm benefits and cost share.

Reimbursement for telehealth visits will follow regulatory guidelines. For eligible telehealth visits, please use Place of Service (POS) 02 and Modifier 95 when submitting your professional (CMS) claims for these visits.

This cost share waiver does not automatically apply to self-funded customers. Please contact the third-party administrator (TPA) to find out whether cost share applies to a member in a self-funded benefit plan. The Self-Funded TPA contact information can be found on the member's id card.

**11. Will providers have an alternative solution for the submission of requested documents for claims payments or will Kaiser Permanente Insurance Company be waiving the requirement to submit requested documents during this time?**

No, we will not be waiving the requirement to submit required requested documentation for claims, except where regulators have explicitly suspended or modified applicable rules. Should providers be unable to submit requested documentation, the claim will be denied. If claim is denied for lack of requested information, providers will still have an opportunity to re-file and submit the requested information to Kaiser Permanente Insurance Company within the timely filing period.

**12. Will providers be able to submit disputes online during this time?**

No, Kaiser Permanente Insurance Company does not have provider dispute online capabilities. Please continue to submit your disputes via mail to the address on the back of the Member's Id Card.

**13. What is the status of the temporary suspension of "Medicare Sequestration" under the CARES Act and the Consolidated Appropriations Act?**

**The CARES Act: Sec. 3709. Adjustment of Sequestration 2020** states that during the period beginning on May 1, 2020 and ending on December 31, 2020, the Medicare programs under title XVII of the Social Security Act (42 U.S.C. 1395 et seq.) shall be exempt from any reduction under any sequestration order issued before, on, or after the date of enactment of this Act. The Consolidated Appropriations Act 2021 extended the end date of the temporary suspension of sequestration to March 31, 2021. An Act to Prevent Across-the-Board Direct Spending Cuts, and for Other Purposes, signed into law on April 14, 2021, extends the suspension period to December 31, 2021.

**14. May providers which bill on an institutional UB-04 claim form bill for telehealth services?**

Notwithstanding CMS guidelines, Kaiser Permanente Insurance Company may allow certain institutional providers (e.g., those providers who typically bill on a UB-04 institutional claim form) to perform telehealth visits under certain circumstances.

**15. Is KP modifying Medicare rates in accordance with the CARES Act?**

In compliance of section 3710 of the CARES Act, Kaiser Permanente will increase the payment made to a hospital for COVID-19 admissions by a 20% increase to the DRG weight starting on January 27, 2020 for Medicare and March 27, 2020 for Commercial through the end of the COVID-19 emergency, as declared by the HHS secretary under the PHSA Section 319.

The 20% add on applies to providers that have Medicare contract rates using pricing calculated by the MS DRG (weight).

For claims using a COVID related ICD-10 diagnosis code, and using the Medicare weighting, Kaiser will reimburse with the 20% weight increase for discharges on or after 4/1/2020.

**16. Will Kaiser Permanente modify their Claims Payment Policy in accordance with COVID-19 guidelines?**

Yes, effective beginning with dates of receipt April 15, 2020, Kaiser has modified its Claims Payment Policy to align with CMS guidance regarding the payment of COVID-19-related claims. Certain services that would have otherwise been disallowed in the ordinary course of the review of COVID-19 related claims, will now be allowed. The Claims Payment Policy may continue to be revised at KPIC's discretion.

**17. What is Kaiser Permanente's position on cost share and reimbursement for serology (antibody) testing?**

Kaiser Permanente will comply with all regulations and requirements for serology testing and effective dates. Covid-19 specific antibody testing procedure codes 86328 and 86769 are not subject to member cost share. Kaiser Permanente is following local Medicare Administrative Contractors (MACs) reimbursement amounts in their respective jurisdictions until Medicare establishes national payment rates.